The risk of inflammatory bowel disease in patients with axial spondyloarthritis treated with biologic agents : BSRBR-AS and meta-analysis

View/Open
Macfarlane_etal_JOR_The_risk_of_AAM.pdf (1.131Mb)
Publication date
01/07/2022
Author
Metadata
Show full item record
Citation
Macfarlane , G , Biallas , R , Dean , LE , Jones , GT , Goodson , N J & Rotariu , O 2022 , ' The risk of inflammatory bowel disease in patients with axial spondyloarthritis treated with biologic agents : BSRBR-AS and meta-analysis ' , Journal of Rheumatology . https://doi.org/10.3899/jrheum.211034
URI
https://hdl.handle.net/2164/19714
DOI
https://doi.org/10.3899/jrheum.211034
Rights
This is a pre-copyediting, author-produced PDF of an article accepted for publication in The Journal of Rheumatology following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxx [insert URL for fully published article in The Journal of Rheumatology website].
Collections